Publication Name	World Journal of Gastroenterology
Manuscript ID	8038
Country	Poland

Received	2013-12-12 16:43
Peer-Review Started	2013-12-12 19:00
To Make the First Decision	2014-01-15 13:28
Return for Revision	2014-01-20 18:41
Revised	2014-02-18 04:41
Second Decision	2014-03-10 15:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-03-10 16:53
Articles in Press	2014-05-23 11:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-28 19:36
Publish the Manuscript Online	2014-06-16 16:19

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Serum adipokines in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Marek Waluga, Marek Hartleb, Grzegorz Boryczka, Michał Kukla and Krystyna Żwirska-Korczala
Funding Agency and Grant Number	Funding Agency Grant Number Medical University of Silesia KNW-1-119/P/1/0
Corresponding Author	Marek Waluga, MD, PhD, Department of Gastroenterology and Hepatology, Medical University of Silesia, ul. Medyków 14, 40-752 Katowice, Poland. mwaluga@sum.edu.pl
Key Words	Adipokines; Tumor growth factor-β1; Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease
Core Tip	Recently, many adipokines with varying metabolic effects have been discovered. A bidirectional interaction between inflammation of the gut and visceral fat may exist in cases of inflammatory bowel disease (IBD). In this work, plasma levels of selected adipokines were studied in subjects with Crohn’s disease and ulcerative colitis before treatment and after achieving clinical remission. The results of this study indicate that IBD modulates serum adipokine levels by stimulating resistin and visfatin release and suppressing leptin production.
Publish Date	2014-06-16 16:19
Citation	Waluga M, Hartleb M, Boryczka G, Kukla M, Żwirska-Korczala K. Serum adipokines in inflammatory bowel disease. World J Gastroenterol 2014; 20(22): 6912-6917
URL	http://www.wjgnet.com/1007-9327/full/v20/i22/6912.htm
DOI	10.3748/wjg.v20.i22.6912

Full Article (PDF)	WJG-20-6912.pdf
Full Article (Word)	WJG-20-6912.doc
Manuscript File	8038-Review.docx
Answering Reviewers	8038-Answering reviewers.pdf
Copyright License Agreement	8038-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	8038-Language certificate.pdf
Peer-review Report	8038-Peer review(s).pdf
Scientific Editor Work List	8038-Scientific editor work list.doc